PATENT COOPERATION TREATY

PCT

REC'D.	4 FEB 2005
WIPO	PCT
)KI	

INTERNATIONAL PRELIMINARY EXAMINATION REPO

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference DURE034 WO	FOR FURTHER ACTION	See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)		
International application No.	International filing date (day/mo	onth/year) Priority date (day/month/year)		
PCT/US02/28519 06 September 2002 (06.09.2002)				
International Patent Classification (IPC)				
IPC(7): A61K 31/66, 31/553 and US Cl.	.: 514/119, 211.09			
Applicant				
DURECT CORPORATION				
This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.				
2. This REPORT consists of	a total of 3 sheets, including	g this cover sheet.		
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).				
These annexes consist of a				
3. This report contains indicate	ations relating to the following	g items:		
I Basis of the rep	ort			
II Priority				
III Non-establishm	ent of report with regard to no	ovelty, inventive step and industrial applicability		
IV Lack of unity o	f invention			
		3-11-5 July 2 3 11 3 11 3 11 3 11 3 11 3 11 3 11 3		
VIII Certain observa	tions on the international appli	ncánon		
Date of submission of the demand	Date	e of completion of this report		
06 April 2004 (06.04.2004) 19 January 2005 (19.01.2005)				
Name and mailing address of the IPEA/US Mail Stop PCT, Aun: IPEA/US		Authorized officer Raymond J Henley III Janual Foul Telephone No. 571-272-1600		
Commissioner for Patents P.O. Box 1450	Ray	ymond J Henley III Janua Four		
Alexandria, Virginia 22313-1450 Foscipile No. (703) 305-3230 Telephone No. 571-272-1600				
Facsimile No. (703) 305-3230	000	- Au		



International application No.	
DGT (1000 (00510	
PCT/US02/28519	

I.	Basi	s of the report
1.	With	regard to the elements of the international application:*
	\boxtimes	the international application as originally filed.
	\boxtimes	the description:
		pages 1-36 as originally filed
		pages NONE , filed with the demand
	<u>~~</u>	pages NONE, filed with the letter of
	\boxtimes	the claims:
		pages NONE as originally filed
		pages 37-39, as amended (together with any statement) under Article 19 pages NONE, filed with the demand
		pages NONE , filed with the letter of
	\square	the drawings:
	لحكا	pages 1-7 , as originally filed
		pages NONE, filed with the demand
		pages NONE , filed with the letter of
		the sequence listing part of the description:
		pages NONE , as originally filed
	•	pages NONE , filed with the demand
_	****	pages NONE , filed with the letter of
2.		h regard to the language, all the elements marked above were available or furnished to this Authority in the uage in which the international application was filed, unless otherwise indicated under this item.
		se elements were available or furnished to this Authority in the following language which is:
	П	the language of a translation furnished for the purposes of international search (under Rule23.1(b)).
	П	the language of publication of the international application (under Rule 48.3(b)).
		the language of the translation furnished for the purposes of international preliminary examination (under Rules
		55.2 and/or 55.3).
3.		h regard to any nucleotide and/or amino acid sequence disclosed in the international application, the
	inte	mational preliminary examination was carried out on the basis of the sequence listing:
	Щ	contained in the international application in printed form.
	\sqsubseteq	filed together with the international application in computer readable form.
		furnished subsequently to this Authority in written form.
		furnished subsequently to this Authority in computer readable form.
		The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the
		international application as filed has been furnished.
		The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.
4.		The amendments have resulted in the cancellation of:
		the description, pages NONE
		the claims, Nos. NONE
		the drawings, sheets/fig NONE
5.	П	This report has been established as if (some of) the amendments had not been made, since they have been considered to go
J.	لــا	beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
thi	s rep	ncement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in ort as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17). replacement sheet containing such amendments must be referred to under item 1 and annexed to this report.



International application No. PCT/US02/28519

1. STATEMENT Novelty (N) Claims 7-18 Claims 1-6 NO Inventive Step (IS) Claims 7-18 Claims 1-6 NO Industrial Applicability (IA) Claims 1-18 Claims 1-18	V. Reasoned statement under Rule 66.2(a)(i citations and explanations supporting such		ve step or industrial applicability;
Inventive Step (IS) Claims 1-6 Claims 1-6 Claims 1-6 Claims 1-18	1. STATEMENT		
Claims 1-6 NO Industrial Applicability (IA) Claims 1-18 1-18 NONE Claims 1-18 NON	Novelty (N)		
Industrial Applicability (IA) Claims 1-18 YES Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-6 do not meet the criteria under PCT Article 33(2) for novelty because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(2) for novelty because the prior art fails to teach the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-6 do not meet the criteria under PCT Article 33(3) for inventive step because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(3) for inventive step because the prior art fails to teach or suggest the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-18 meet the criteria under PCT Article 33(4) because pharmaceutical compositions comprising the claimed NMDA receptor antagonists; system for delivery of a drug to the round window membrane of the inner ear; and method for treating an inner ear disorder would each have applicability in the medical inclustry.	Inventive Step (IS)		
Claims NONE NO 2. CITATIONS AND EXPLANATIONS Claims 1-6 do not meet the criteria under PCT Article 33(2) for novelty because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(2) for novelty because the prior art fails to teach the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-6 do not meet the criteria under PCT Article 33(3) for inventive step because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(3) for inventive step because the prior art fails to teach or suggest the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-18 meet the criteria under PCT Article 33(4) because pharmaceutical compositions comprising the claimed NMDA receptor antagonists; system for delivery of a drug to the round window membrane of the inner ear; and method for treating an inner ear disorder would each have applicability in the medical inclustry.	Industrial Applicability (IA)		VEC
Claims 1-6 do not meet the criteria under PCT Article 33(2) for novelty because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(2) for novelty because the prior art fails to teach the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-6 do not meet the criteria under PCT Article 33(3) for inventive step because OLNEY (U.S. Patent No. 5,039,528) teaches pharmaceutical compositions comprising the claimed NMDA receptor antagonist. The statements of intended use or function in the claims fail to distinguish the claimed compositions from those of the prior art because such statements fails to impart any physical feature to the claimed compositions that is not found in the prior art composition. Claims 7-18 meet the criteria under PCT Article 33(3) for inventive step because the prior art fails to teach or suggest the presently claimed system for delivery of a drug to the round window membrane of the inner ear or method for treating an inner ear disorder. Claims 1-18 meet the criteria under PCT Article 33(4) because pharmaceutical compositions comprising the claimed NMDA receptor antagonists; system for delivery of a drug to the round window membrane of the inner ear; and method for treating an inner ear disorder would each have applicability in the medical industry.			·····
	teaches pharmaceutical compositions comprising the in the claims fail to distinguish the claimed composit physical feature to the claimed compositions that is a Claims 7-18 meet the criteria under PCT A system for delivery of a drug to the round window and Claims 1-6 do not meet the criteria under 5,039,528) teaches pharmaceutical compositions corror function in the claims fail to distinguish the claim impart any physical feature to the claimed compositions Claims 7-18 meet the criteria under PCT A presently claimed system for delivery of a drug to the disorder. Claims 1-18 meet the criteria under PCT A NMDA receptor antagonists; system for delivery of an inner ear disorder would each have applicability in the claims and the compositions compositions.	claimed NMDA receptor antagonist. ions from those of the prior art because of found in the prior art composition. Tricle 33(2) for novelty because the prior membrane of the inner ear or method for the composition of the inner ear or method for the compositions from those of the prior art compositions are compositions.	The statements of intended use or function e such statements fails to impart any ior art fails to teach the presently claimed or treating an inner ear disorder. Eccause OLNEY (U.S. Patent No. antagonist. The statements of intended use or art because such statements fails to imposition. The prior art fails to teach or suggest the er ear or method for treating an inner ear iompositions comprising the claimed

International application No.
PCT/US02/28519

A. CLASSIFICATION OF SUBJECT MATTER IPC(7): A61K 31/66, 31/558 US CL: 514/119, 211.09 According to International Patent Classification (IPC) or to b B. FIELDS SEARCHED Minimum documentation searched (classification system follow U.S.: 514/119, 211.09 Documentation searched other than minimum documentation searched	wed by classification symbols)	ncluded in the fields
Electronic data base consulted during the international search	n (name of data base and, where practicable	e, search terms used)
C. DOCUMENTS CONSIDERED TO BE RELEVANT	r	
Category* Citation of document, with indication, where	appropriate, of the relevant passages	Relevant to claim No.
X	lumn 13, lines 12-19.	13-14 1-12 and 15-21
Further documents are listed in the continuation of Bo Special categories of cited documents: "A" document defining the general state of the art which is not considere to be of particular relevance "E" earlier document published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which cited to establish the publication date of another citation or othe special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or othe means "P" document published prior to the international filing date but late than the priority date claimed Date of the actual completion of the international search	"X" later document published after the int date and not in conflict with the app the principle or theory underlying the document of particular relevance; the considered novel or cannot be considered to involve an inventive step with one or more other such document of particular relevance; the considered to involve an inventive step with one or more other such document of particular nelevance; the considered to involve an inventive step with one or more other such document of particular nelevance; the considered to involve an inventive step with one or more other such document of particular nelevance; the considered new particular nelevance; the considered nelevance nel	dication but cited to understand to invention as claimed invention cannot be the claimed inve
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703) 305-3230	Authorized Tilice RAYMOND J. HENLEY III Telephone No. (708) 308-1285	ida